The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: Results from the ACT-RAY MRI substudy

Annals of the Rheumatic Diseases

Volumn 73, Issue 5, 2014, Pages 810-816

  Conaghan, Philip G ^a   Peterfy, Charles ^b   Olech, Ewa ^c   Kaine, Jeffrey ^d   Ridley, David ^e   DiCarlo, Julie ^b   Friedman, Josh ^f   Devenport, Jenny ^f   Troum, Orrin ^g  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b Spire Sciences Inc   (United States)

^c UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^d Sarasota Arthritis Center   (United States)

^e Saint Paul Rheumatology   (United States)

^f GENENTECH INC   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; PLACEBO; TOCILIZUMAB;

ADULT; ARTICLE; BONE EROSION; CONTROLLED STUDY; DAS28; DISEASE COURSE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEITIS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHEUMATOLOGY RHEUMATOID ARTHRITIS MAGNETIC RESONANCE IMAGING SCORE; SYNOVITIS;

DISEASE ACTIVITY; DMARDS (BIOLOGIC); MAGNETIC RESONANCE IMAGING; RHEUMATOID ARTHRITIS; SYNOVITIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; JOINTS; MAGNETIC RESONANCE IMAGING; MALE; METHOTREXATE; MIDDLE AGED; OSTEITIS; SYNOVITIS; TREATMENT OUTCOME;

EID: 84897983379     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204762     Document Type: Article

References (38)

1. Chen TS, Crues JV 3rd, Ali M, et al. Magnetic resonance imaging is more sensitive than radiographs in detecting change in size of erosions in rheumatoid arthritis. J Rheumatol 2006;33:1957-67. (Pubitemid 44571867)
2. McGonagle D, Conaghan PG, O'Connor P, et al. The relationship between synovitis and bone changes in early untreated rheumatoid arthritis: a controlled magnetic resonance imaging study. Arthritis Rheum 1999;42:1706-11. (Pubitemid 30263640)
3. Ostergaard M, Emery P, Conaghan PG, et al. Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients. Arthritis Rheum 2011;63:3712-22.
4. Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008;58:1299-309. (Pubitemid 351705919)
5. Dougados M, Devauchelle-Pensec V, Ferlet JF, et al. The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound. Ann Rheum Dis 2013;72:665-71.
6. Aletaha D, Smolen JS. Joint damage in rheumatoid arthritis progresses in remission according to the disease activity score in 28 joints and is driven by residual swollen joints. Arthritis Rheum 2011;63:3702-11.
7. Gandjbakhch F, Conaghan PG, Ejbjerg B, et al. Synovitis and osteitis are very frequent in rheumatoid arthritis clinical remission: results from an MRI study of 294 patients in clinical remission or low disease activity state. J Rheumatol 2011;38:2039-44.
8. Ranganath VK, Strand V, Peterfy CG, et al. The utility of magnetic resonance imaging for assessing structural damage in randomized controlled trials in rheumatoid arthritis: report from the imaging group of the American College of Rheumatology RA clinical trials task force. Arthritis Rheum 2013;65:2513-23.
9. Peterfy C, Ostergaard M, Conaghan PG. MRI comes of age in RA clinical trials. Ann Rheum Dis 2013;72:794-6.
10. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
11. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80.
12. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97. (Pubitemid 351392039)
13. Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial oftocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63:609-21.
14. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96.
15. Dougados M, Kissel K, Conaghan PG, et al. Clinical, radiographic, and immunological effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 2014;73: 803-9.
16. Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013;72:43-50.
17. Peterfy CG, Olech E, DiCarlo JC, et al. Monitoring cartilage loss in the hands and wrists in rheumatoid arthritis with magnetic resonance imaging in a multi-center clinical trial: IMPRESS (NCT00425932). Arthritis Res Ther 2013;15:R44.
18. Peterfy C, Troum O, Olech E, et al. Discriminative power of different combinations of bones and joints for assessing change in rheumatoid arthritis with low-field MRI.Ann Rheum Dis 2010;69:119.
19. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:27-35. (Pubitemid 40129229)
20. Bruynesteyn K, Boers M, Kostense P, et al. Deciding on progression of joint damage in paired films of individual patients: Smallest detectable difference or change. Ann Rheum Dis 2005;64:179-82. (Pubitemid 40193607)
21. Conaghan PG, Emery P, Ostergaard M, et al. Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial. Ann Rheum Dis 2011;70:1968-74.
22. Durez P, Malghem J, Nzeusseu Toukap A, et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum 2007;56:3919-27. (Pubitemid 350262784)
23. Conaghan PG, O'Connor P, McGonagle D, et al. Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis Rheum 2003;48:64-71. (Pubitemid 36091649)
24. Conaghan PG, Durez P, Alten RE, et al. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Ann Rheum Dis 2013;72:1287-94.
25. Dougados M, Kissel K, Conaghan PG, et al. Clinical, radiographic, and immunogenic effects after 1 year of tocilizumab-based treatment strategy with and without methotrexate in rheumatoid arthritis: the ACT-RAY study. Arthritis Rheum 2012;64:2550.
26. Ostergaard M, Pedersen SJ, Dohn UM. Imaging in rheumatoid arthritis - status and recent advances for magnetic resonance imaging, ultrasonography, computed tomography and conventional radiography. Best Pract Res Clin Rheumatol 2008;22:1019-44.
27. Hoving JL, Buchbinder R, Hall S, et al. A comparison of magnetic resonance imaging, sonography, and radiography of the hand in patients with early rheumatoid arthritis. J Rheumatol 2004;31:663-75. (Pubitemid 38451251)
28. Klarlund M, Ostergaard M, Jensen KE, et al. Magnetic resonance imaging, radiography, and scintigraphy of the finger joints: one year follow up of patients with early arthritis. The TIRA Group. Ann Rheum Dis 2000;59:521-8. (Pubitemid 30445830)
29. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2012;51(Suppl 5):v3-11.
30. Samson M, Audia S, Janikashvili N, et al. Brief report: Inhibition of interleukin-6 function corrects Th17/treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum 2012;64:2499-503.
31. Ostergaard M, Conaghan PG, O'Connor P, et al. Reducing invasiveness, duration, and cost of magnetic resonance imaging in rheumatoid arthritis by omitting intravenous contrast injection - does it change the assessment of inflammatory and destructive joint changes by the OMERACT RAMRIS? J Rheumatol 2009;36:1806-10.
32. Taouli B, Zaim S, Peterfy CG, et al. Rheumatoid arthritis of the hand and wrist: Comparison of three imaging techniques. AJR Am J Roentgenol 2004;182:937-43. (Pubitemid 38391654)
33. Peterfy C, Olech E, Gaylis N, et al. Comparison of 1.5 T whole-body MRI and 0.2 T extremity MRI for monitoring rheumatoid arthritis in a multi-site clinical trial (IMPRESS). Ann Rheum Dis 2011;70:368.
34. Genovese MC, Kavanaugh A, Weinblatt ME, et al. An oral syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 2011;63:337-45.
35. Peterfy C, Haraoui B, Kavanaugh A, et al. Baseline levels of the inflammatory biomarker C-reactive protein are significantly correlated with magnetic resonance imaging measures of synovitis at baseline and after 26 weeks of treatment in patients with early rheumatoid arthritis. Arthritis Rheum 2011;63:1612.
36. Peterfy C, Emery P, Tak PP, et al. Rituximab (RTX) plus methotrexate (MTX) prevents bone erosion and joint-space narrowing (JSN) and reduces synovitis, osteitis as shown on MRI: results from a randomised, placebo-controlled trial in patients (pts) with rheumatoid arthritis (RA-SCORE). Ann Rheum Dis 2011;70:152.
37. Peterfy CG, Emery P, Genovese MC, et al. Magnetic resonance imaging substudy ina phase 2b dose-ranging study of baricitinib, an oral Janus kinase 1/Janus kinase 2 inhibitor, in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Rheum 2012;64:2488.
38. Beals C, Baumgartner R, Peterfy C, et al. Treatment effects measured by dynamic contrast enhanced MRI and RAMRIS for rheumatoid arthritis. Ann Rheum Dis 2013;72:748